Tiziana Life Sciences Ltd (TLSA)

Revance Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.72	1.18	18.12	42.19	65.82
Cash & Short-Term Investments	3.72	1.18	18.12	42.19	65.82
Cash Growth	214.79%	-93.47%	-57.04%	-35.91%	32812.00%
Accounts Receivable	-	-	-	-	0.15
Other Receivables	3.64	5.93	5.86	5.27	3.5
Receivables	3.64	5.93	5.86	5.27	3.65
Prepaid Expenses	0.09	0.1	0.17	1.19	0.38
Other Current Assets	0.05	0.12	0.13	0.04	0.33
Total Current Assets	7.51	7.34	24.28	48.68	70.18
Property, Plant & Equipment	0.19	0.29	0.39	0.02	0.36
Long-Term Investments	3.59	4.55	1.81	-	-
Other Intangible Assets	-	-	-	0.13	0.12
Total Assets	11.28	12.18	26.48	48.83	70.66
Accounts Payable	5.58	4.14	4.96	4.41	3.37
Accrued Expenses	1.65	2.25	1.57	1.78	2.22
Current Portion of Leases	0.11	0.14	0.12	-	0.27
Other Current Liabilities	0.01	0.01	0.01	1.37	2.13
Total Current Liabilities	7.35	6.54	6.66	7.55	7.98
Long-Term Leases	-	0.11	0.24	-	0.29
Total Liabilities	7.35	6.65	6.91	7.55	8.27
Common Stock	0.11	0.1	0.1	0.1	0.1
Additional Paid-In Capital	23.11	16.49	15.6	15.6	-
Retained Earnings	-144.83	-133.68	-116.26	-108.06	-84.65
Treasury Stock	-	-1.57	-1.32	-	-
Comprehensive Income & Other	125.55	124.19	121.46	133.65	146.94
Shareholders' Equity	3.94	5.54	19.57	41.28	62.39
Total Liabilities & Equity	11.28	12.18	26.48	48.83	70.66
Total Debt	0.11	0.25	0.37	-	0.56
Net Cash (Debt)	3.62	0.94	17.76	42.19	65.27
Net Cash Growth	286.54%	-94.73%	-57.91%	-35.37%	-
Net Cash Per Share	0.03	0.01	0.17	0.43	0.67
Filing Date Shares Outstanding	111.46	101.51	100.59	102.27	194.61
Total Common Shares Outstanding	111.46	101.51	100.59	102.27	194.61
Working Capital	0.16	0.8	17.62	41.13	62.2
Book Value Per Share	0.04	0.05	0.19	0.40	0.32
Tangible Book Value	3.94	5.54	19.57	41.15	62.27
Tangible Book Value Per Share	0.04	0.05	0.19	0.40	0.32
Machinery	-	-	-	-	0.06

Updated Oct 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q